key: cord-0799087-nqot0ebj authors: Rinaldi, Matteo; Bartoletti, Michele; Bussini, Linda; Pancaldi, Livia; Pascale, Renato; Comai, Giorgia; Morelli, Mariacristina; Ravaioli, Matteo; Cescon, Matteo; Cristini, Francesco; Viale, Pierluigi; Giannella, Maddalena title: COVID‐19 in solid organ transplant recipients: No difference in survival compared to general population date: 2020-08-02 journal: Transpl Infect Dis DOI: 10.1111/tid.13421 sha: 2a4f5c84ed153601208b6f997f753a5c694fd7eb doc_id: 799087 cord_uid: nqot0ebj Coronavirus disease 2019 (COVID‐19) may be associated with worse outcome in solid organ transplant (SOT) recipients. We performed a prospective cohort study of hospitalized patients with confirmed diagnosis of COVID‐19, from March 15 to April 30, 2020, at two tertiary hospitals in Emilia‐Romagna Region. SOT recipients were compared with non‐SOT patients. Primary endpoint was all‐cause 30‐day mortality. Relationship between SOT status and mortality was investigated by univariable and multivariable Cox regression analysis. Patients were assessed from COVID‐19 diagnosis to death or 30‐day whichever occurred first. Study cohort consisted of 885 patients, of them 24 SOT recipients (n = 22, kidney, n = 2 liver). SOT recipients were younger, had lower BMI, but higher Charlson Index. At admission they presented less frequently with fever and respiratory failure. No difference in 30‐day mortality between the two groups (19% vs 22.1%) was found; however, there was a trend toward higher rate of respiratory failure (50% vs 33.1%, P = .07) in SOT recipients. Superinfections were more represented in SOT recipients, (50% vs 15.5%, P < .001). At multivariate analysis adjusted for main covariates, there was no association between SOT and 30‐day mortality HR 1.15 (95% CI 0.39‐3.35) P = .79. Our data suggest that mortality among COVID‐19 SOT recipients is similar to general population. patients diagnosed with COVID-19 have reported high morbidity and mortality, with intensive care unit admission and mortality rates ranging from 0%-39% to 0%-50%, respectively. [4] [5] [6] [7] [8] [9] [10] However, data on differences in symptoms, clinical severity, treatment management and outcome between SOT and non-SOT patients hospitalized with COVID-19 have yet to be investigated. We performed a prospective multicenter cohort study of hospitalized patients with COVID-19 diagnosis to compare clinical presentation, therapeutic management and outcome between SOT and non-SOT recipients. Prospective cohort study of adult patients hospitalized at Sant'Orsola-Malpighi Hospital and Rimini Hospital, from March 15 to April 30 , 2020. Patients with detection of SARS-CoV-2 by RT-PCR on respiratory specimens were included. Patients were followed up to death, or hospital discharge. Diagnostic testing for COVID-19 and hospitalization was performed according to local policy and clinical judgment, and were not dictated by study protocol. Local microbiology databases were used to identify patients. Clinical charts and hospital electronic records were used as data sources. Data were collected de-identified and managed using REDCap electronic data capture tools hosted at University of Bologna. 11, 12 The study was approved by the Ethic Committee of the promoting center (Comitato Etico Indipendente di Area Vasta Emilia Centro, n. 283/2020/Oss/ AOUBo). Primary endpoint was all-cause 30-day mortality. Secondary endpoints included severe respiratory failure and length of hospital stay. Severe respiratory failure was assessed from diagnosis to hospital discharge and defined according to World and Health Organization (WHO) criteria as: SpO 2 <93% with 100% FiO 2 (reservoir mask or continuous positive airway pressure ventilation or other non-invasive ventilation), respiratory rate >30 bpm, or respiratory distress (https://www.who.int/publi catio ns-detai l/clini cal-manag ement -of-sever e-acute -respi rator y-infec tionwhen-novel -coron aviru s-(ncov)-infec tion-is-suspe cted, accessed 5 April 2020). 15 Diagnostic testing for infection and its etiology was performed by attending physicians and was not dictated by study protocol. were introduced in a Cox regression model adjusted for the SOT condition. Patients were considered from COVID-19 diagnosis to death or 30-days. Statistical significance was considered for P <05. All analysis was performed with SPSS 21.0. Study cohort consisted of 885 hospitalized patients with COVID-19 diagnosis: median age was 69 (IQR 57-80) years, 66.9% were male (see Table 1 ). Overall, 24 SOT patients were included: 22 Disease severity at admission Needing of oxygen support 462 (52. Charlson Index, increased respiratory rate, LDH, elevated C-reactive protein, and SOFA score. Female sex was found to be protective (Table 2) . Therefore, SOT was not associated with increased risk of death ( Figure 1 ). Management of SOT recipients diagnosed of COVID-19 is challenging. Although initial clinical presentation is milder compared to general population, progression toward severe respiratory failure is more frequent than in non-SOT recipients. However, there was no significant difference in 30-day survival between SOT recipients and general population, also when adjusted for potential confounders. SOT recipients showed higher rates of superinfection than non-SOT patients with longer duration of hospital stay, confirming the high impact of COVID-19 on morbidity of SOT patients. In our study, the median time from transplant to COVID-19 diagnosis was shorter compared to other series. 5 Previous case series [5] [6] [7] [8] [9] of SOT recipients showed high in-hospital mortality rates ranging from 24% to 32%. In our study, mortality rates in SOT and non-SOT patients were similar around 20%. Considering the high incidence of severe respiratory failure among SOT recipients, these relatively low mortality rates may reflect a massive use of healthcare resources. This assumption is supported by early hospitalization, a significant major use of novel immunosuppressive drugs, such as IL-6 inhibitors, and a greater ease of access to ICU. however, it could not consider any late complication of the disease. To conclude, our study underlines difficulties in the management of SOT patients with COVID-19. Careful assessment seems to be important for recognizing patients at risk of complicated course. Risk-benefit balance of using novel immunosuppressive drugs in this setting should be investigated in larger studies. No funding was received for this project. Authors declare no conflict of interest related to the content of the present manuscript. MR involved in data collection, data analysis, and drafting the manu- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Novel coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients COVID-19 in solid organ transplant recipients: a single-center case series from Spain Covid-19 and kidney transplantation A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia Characteristics and outcomes of recipients of heart transplant with coronavirus disease COVID-19 in solid organ transplant recipients: Initial report from the US epicenter COVID-19 in kidney transplant recipients Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support The REDCap consortium: building an international community of software platform partners Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) Consensus Group Additional supporting information may be found online in the Supporting Information section.